Mycophenolate Mofetil (MMF) + Thymoglobulin + Sirolimus
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies, Myelodysplastic Syndrome, Leukemia, Lymphoma
Trial Timeline
Sep 1, 2006 → Oct 1, 2010
NCT ID
NCT00506948About Mycophenolate Mofetil (MMF) + Thymoglobulin + Sirolimus
Mycophenolate Mofetil (MMF) + Thymoglobulin + Sirolimus is a phase 2 stage product being developed by Sanofi for Hematological Malignancies. The current trial status is terminated. This product is registered under clinical trial identifier NCT00506948. Target conditions include Hematological Malignancies, Myelodysplastic Syndrome, Leukemia.
What happened to similar drugs?
0 of 1 similar drugs in Hematological Malignancies were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00506948 | Phase 2 | Terminated |
Competing Products
20 competing products in Hematological Malignancies